| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Ipratropium-d3 bromide targets muscarinic acetylcholine receptors (M1, M2, M3) in the airways as a competitive antagonist, the same as unlabeled ipratropium. However, the d3 version is intended solely as an analytical standard and is not used in pharmacological activity assays. The three deuterium atoms provide a mass shift of +3 Da for mass spectrometry detection.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as tracers for quantification throughout the drug development process. Due to its potential to alter the pharmacokinetic and metabolic characteristics of medications, deuteration has drawn attention[1].
The unlabeled ipratropium bromide is a competitive antagonist at M3 receptors; in cell-free membrane preparations, it displaces [3H]-N-methylscopolamine with a Ki in the sub-nanomolar range. Ipratropium-d3 is not used in these assays; instead, it serves as an internal standard for the quantification of unlabeled drug in samples from such assays. |
| ln Vivo |
In cell-based functional assays (e.g., carbachol-induced contraction of airway smooth muscle cells), unlabeled ipratropium potently inhibits contraction (IC50 in nM range). Ipratropium-d3 is not added to these bioactivity assays; it is used exclusively for analytical quantification of drug levels in cell lysates or media from those experiments.
|
| Enzyme Assay |
For LC-MS/MS method development, Ipratropium-d3 bromide is used as an internal standard. Known amounts of unlabeled ipratropium bromide are spiked into blank biological matrices (plasma, urine, tissue homogenates) along with a fixed concentration of Ipratropium-d3. After sample preparation (protein precipitation, SPE), extracts are analyzed by LC-MS/MS. The peak area ratio (unlabeled/d3) is used to construct a calibration curve.
|
| Cell Assay |
Cells (e.g., human bronchial epithelial cells) are treated with unlabeled ipratropium bromide (0.1-100 nM) for defined periods. Cells are lysed, and the lysate is spiked with Ipratropium-d3 as an internal standard. After extraction, ipratropium concentrations are quantified by LC-MS/MS. This allows measurement of cellular uptake and efflux kinetics. No flow cytometry or functional readouts are performed with the d3 standard.
|
| Animal Protocol |
In animal pharmacokinetic studies, Ipratropium-d3 is used as an internal standard, not as a dosed tracer. Animals (rats or dogs) receive unlabeled ipratropium bromide via inhalation or IV. Blood samples are collected at various time points. Plasma samples are processed with a fixed amount of Ipratropium-d3 added as an internal standard before extraction. LC-MS/MS analysis quantifies ipratropium levels, and PK parameters (half-life, clearance, volume of distribution) are calculated.
|
| ADME/Pharmacokinetics |
Ipratropium-d3 has the same physicochemical and PK properties as unlabeled ipratropium: low oral bioavailability, rapid clearance after inhalation (systemic half-life 2-4 hours), and metabolism by esterases. The deuterium label does not cause an isotopic effect that alters PK. The compound is stable in plasma and during sample storage. It is stored as a powder at -20degC, protected from light.
|
| Toxicity/Toxicokinetics |
Ipratropium-d3 is used in minute quantities and does not contribute to toxicity. The unlabeled parent drug is safe at therapeutic doses; adverse effects are mild and dose-dependent (dry mouth, cough). The d3 label does not introduce new toxicities. Standard laboratory safety practices are sufficient. Not for human use.
|
| References |
|
| Additional Infomation |
Ipratropium-d3 is a stable isotope-labeled internal standard for the quantitative analysis of ipratropium in biological matrices. It is used in pharmaceutical research for bioequivalence, pharmacokinetic, and metabolism studies. The d3 label provides a +3 Da mass shift, allowing differentiation from endogenous compounds and the parent drug. The product is for research use only and is not intended for clinical or therapeutic applications.
|
| Molecular Formula |
C20H27D3BRNO3
|
|---|---|
| Molecular Weight |
415.38
|
| Related CAS # |
Ipratropium bromide;22254-24-6;Ipratropium bromide hydrate;66985-17-9
|
| Appearance |
Light yellow to yellow solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
|---|
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4074 mL | 12.0372 mL | 24.0743 mL | |
| 5 mM | 0.4815 mL | 2.4074 mL | 4.8149 mL | |
| 10 mM | 0.2407 mL | 1.2037 mL | 2.4074 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
